HONG KONG – Chinese clinical-stage cancer drug developer Tot Biopharm International Co. Ltd. has filed an IPO with the Hong Kong Stock Exchange (HKEX), making it the latest pre-revenue applicant for listing on the HKEX, which already has seven pre-profit biotech players listed.
HONG KONG – Chinese clinical-stage cancer drug developer Tot Biopharm International Co. Ltd. has filed an IPO with the Hong Kong Stock Exchange (HKEX), making it the latest pre-revenue applicant for listing on the HKEX, which already has seven pre-profit biotech players listed.
HONG KONG – Edigene Inc., a startup focused on genome editing to develop novel therapeutics for genetic diseases and cancer, has raised a further $10 million during the first half of this year and entered a strategic collaboration with another Chinese biotech.
HONG KONG – Chinese integrated health care group Golden Meditech Holding Ltd. has partnered up with Hong Kong Baptist University (HKBU)'s biology department to conduct research in the area of cell therapy with an aim to treat neurodegenerative diseases with stem cells.
HONG KONG – Hong Kong-based cancer drugmaker Hutchison China Meditech Ltd. (Chi-Med) filed its third IPO, seeking a listing on the Hong Kong Exchange (HKEX) after getting listed on the AIM market of the London Stock Exchange and on Nasdaq. The HK IPO follows a major milestone for the company, which won regulatory approval in China for innovative cancer drug Elunate (fruquintinib) last year.
HONG KONG – Hong Kong-based cancer drugmaker Hutchison China Meditech Ltd. (Chi-Med) filed its third IPO, seeking a listing on the Hong Kong Exchange (HKEX) after getting listed on the AIM market of the London Stock Exchange and on Nasdaq. The HK IPO follows a major milestone for the company, which won regulatory approval in China for innovative cancer drug Elunate (fruquintinib) last year.
